Key clinical point:
Major finding: With a median follow-up of 50.4 months, progression-free survival was not significantly different for escalated BEACOPP vs. the experimental arm (HR, 1.084; 95% CI, 0.73-1.59; P = .68).
Study details: Final analysis of AHL2011 LYSA, a randomized phase 3 study including 823 patients with advanced-stage Hodgkin lymphoma.
Disclosures: Dr. Casasnovas reported financial ties to AbbVie, Bristol-Myers Squibb, Celgene, Gilead Sciences, Janssen, Merck, Roche/Genentech, Sanofi, and Takeda.
Source: Casasnovas O et al. ASCO 2018 (annual meeting of the American Society of Clinical Oncology), Abstract 7503.
Casasnovas O et al. ASCO 2018 (annual meeting of the American Society of Clinical Oncology), Abstract 7503.
This Week's Must Reads
Must Reads in Aggressive Lymphomas
Researchers characterize new subtype of high-grade DLBCL, 3 articles from the Journal of Clinical Oncology